Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting

NEXT STORY
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
PREV STORY
American College of Rheumatology Targets Step Therapy and Drug Pricing in New Position Statements
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer

ALPHARETTA, Ga., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a ...

author_avatar
NASDAQ Market News

Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology

Results demonstrate anti-tumor activity and manageable safety profile of the two dosing regimens of ...

author_avatar
NASDAQ Market News